EOLS Stock Analysis: Buy, Sell, or Hold?

EOLS - Evolus, Inc. Common Stock

PHARMACEUTICAL PREPARATIONS
$3.92
-0.09 (-2.37%) β–Ό
5d: -16.35%
30d: -8.95%
90d: -43.26%
WAIT
LOW Confidence
Protect Your EOLS Gains
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: May 06, 2026
Smart Money Accumulation

EOLS is down 13.6% this week, but smart money is accumulating calls. Top strike: $5 2026-05-15 with 13 OI. Call ratio: 64% View Scanner →

Strength: 8.1/10

Get Alerted When EOLS Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.
100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading chart...

Loading historical data...

πŸ’‘
Bottom Line:
⏸️ WAIT FOR STABILIZATION: EOLS is down 16.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.

Long-Term Wealth Forecast (2031)

Based on Analyst Consensus Growth & Historical Valuation

0% (Stagnation) 50% (Hyper Growth)
EST. PRICE IN 2031
$8.41
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$5.22
25.0% Margin of Safety

How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.

In-depth Analysis How we analyze

Valuation Analysis: EOLS is currently trading at $3.92, which is considered fair relative to its 30-day fair value range of $4.31 to $5.21. From a valuation perspective, the stock is trading at a discount (Forward PE: 16.7) compared to its historical average (36.3). Remarkably, the market is currently pricing in an annual earnings decline of 22.8% over the next few years. This aligns with recent fundamental challenges.

Technical Outlook: Technically, EOLS is in a strong downtrend. The price is currently testing key support at $3.91. A bounce from this level would confirm strength, while a break below could signal further downside.

Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $14.67 (+265.8%). Current signals suggest waiting for a better entry point before initiating new positions.

Quick Decision Summary

Current Position FAIR
Fair Price Range $4.31 - $5.21
Company Quality Score 52/100 (HOLD)
Volume Confirmation HIGH
Confidence Score 72.4%

Protect Your Profits

Holding EOLS? Use our AI-powered strategies to protect your downside while keeping your long-term position.

View Profit Protection Plan

All Signals

  • NEUTRAL: Price in fair range
  • NEUTRAL: Mixed technical signals (40/100)
  • BULLISH: High volume confirmation
  • BULLISH: Trading 265.8% below Wall St target ($14.67)
  • WARNING: Recommendation downgraded due to -16.3% 5-day decline - wait for stabilization

Fair Price Analysis

30-Day Fair Range $4.31 - $5.21
Current vs Fair Value FAIR

Support & Resistance Levels

Support Level $3.91
Resistance Level $5.06
Current Trend Strong Downtrend
Technical data as of Mar 30, 2026

Fundamental Context

Forward P/E (Next Year Est.) 16.71
Wall Street Target $14.67 (+265.8%)
Revenue Growth (YoY) 14.4%
Profit Margin -17.4%
Valuation Discount vs History -22.8% cheaper
PE vs Historical 16.7 vs 36.3 CHEAP
Market-Implied Price Targets If current PE multiple persists
Implied Growth (YoY): -22.8% (market-implied from PE analysis)
1-Year Target $3.61 (-10%)
2-Year Target $3.25 (-19%)
3-Year Target $2.92 (-27%)
3-Yr Target (if PE normalizes) (PE: 17β†’36) $6.35 (+58%)
πŸ’‘ Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 16.7 to 36.3
Stabilization Target: $8.71 (+117.3%)
PE Expansion Potential: +117.3%
Share & Embed Analysis

Found this analysis useful? Share it with your community or embed the live chart on your blog.

Tweet Reddit
bloggers & journalists: you are free to use our charts with attribution.
Last updated: March 30, 2026 2:43 PM ET
Data refreshes hourly during market hours. Next update: 3:43 PM
πŸ”₯ Top Stocks Breaking Out Now
Ticker Score Recommendation Change %
Insider Activity (6 Months)
0
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
David Moatazedi SELL 116720 shares 2026-03-17
Rui Avelar SELL 29996 shares 2026-03-17
David Moatazedi SELL 10539 shares 2025-12-22

Unlock Insider Activity

See real-time buying/selling by company executives for EOLS.

Create Free Account

Already have an account? Log In

Top Rated Drug Manufacturers - Specialty & Generic Stocks

Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.

Stock Analyst Consensus Analyst Target Tradestie Score
NBIX
Neurocrine Biosciences I…
STRONG BUY
25 analysts
$178 63 BUY
ZTS
Zoetis Inc
STRONG BUY
19 analysts
$151 55 HOLD
LNTH
Lantheus Holdings Inc
STRONG BUY
13 analysts
$91 55 HOLD
HCM
HUTCHMED DRC
STRONG BUY
14 analysts
$21 63 BUY
BCRX
BioCryst Pharmaceuticals…
STRONG BUY
12 analysts
$21 56 HOLD

Advanced EOLS Option Strategies

Professional options setups generated by AI based on today's EOLS price and gamma walls.

Iron Condor Bull Call Bear Put Collar

More Analysis for EOLS

EOLS Technical Chart EOLS Price Prediction EOLS Earnings Date EOLS Investment Advisor EOLS Fair Price Analyzer EOLS Options Advisor EOLS Options Chain EOLS Options Analysis EOLS Competitors
Live Trades
From trading groups
Loading trades...
View All Live Trades See Trader Consensus & Signals